These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 20001765

  • 1. A more active treatment has profound effects on the health status of rheumatoid arthritis (RA) patients: results from a population-based RA register in Malmö, Sweden, 1997-2005.
    Söderlin MK, Lindroth Y, Turesson C, Jacobsson LT.
    Scand J Rheumatol; 2010 May; 39(3):206-11. PubMed ID: 20001765
    [Abstract] [Full Text] [Related]

  • 2. Trends in medication and health-related quality of life in a population-based rheumatoid arthritis register in Malmo, Sweden.
    Söderlin MK, Lindroth Y, Jacobsson LT.
    Rheumatology (Oxford); 2007 Aug; 46(8):1355-8. PubMed ID: 17567634
    [Abstract] [Full Text] [Related]

  • 3. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [Abstract] [Full Text] [Related]

  • 4. Differences in longitudinal disease and treatment characteristics of patients with rheumatoid arthritis replying and not replying to a postal questionnaire. Experience from a biologics register in southern Sweden.
    Söderlin MK, Jacobsson LT, Petersson IF, Englund M, Saxne T, Geborek P.
    J Rheumatol; 2009 Jun; 36(6):1166-9. PubMed ID: 19411397
    [Abstract] [Full Text] [Related]

  • 5. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response.
    Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE, Perfetto EM.
    Am J Manag Care; 2002 Mar; 8(3):231-40. PubMed ID: 11915973
    [Abstract] [Full Text] [Related]

  • 6. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
    Valleala H, Korpela M, Möttönen T, Hienonen-Kempas T, Kauppi M, Hannonen P, Leirisalo-Repo M.
    Scand J Rheumatol; 2009 Mar; 38(5):323-7. PubMed ID: 19585384
    [Abstract] [Full Text] [Related]

  • 7. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.
    Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, Dorrier C, Thompson A.
    Arthritis Rheum; 2000 Mar; 43(3):506-14. PubMed ID: 10728742
    [Abstract] [Full Text] [Related]

  • 8. Prescription rheumatology practices among Mexican specialists.
    Goycochea-Robles MV, Arce-Salinas CA, Guzmán-Vázquez S, Cardiel-Ríos MH.
    Arch Med Res; 2007 Apr; 38(3):354-9. PubMed ID: 17350489
    [Abstract] [Full Text] [Related]

  • 9. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis.
    Gonzalez-Alvaro I, Carmona L, Balsa A, Sanmarti R, Belmonte MA, Tena X, EMECAR Study Group.
    J Rheumatol; 2003 Apr; 30(4):697-704. PubMed ID: 12672186
    [Abstract] [Full Text] [Related]

  • 10. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.
    Strand V, Scott DL, Emery P, Kalden JR, Smolen JS, Cannon GW, Tugwell P, Crawford B, Leflunomide Rheumatoid Arthritis Investigators Groups.
    J Rheumatol; 2005 Apr; 32(4):590-601. PubMed ID: 15801012
    [Abstract] [Full Text] [Related]

  • 11. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability.
    Baumgartner SW, Fleischmann RM, Moreland LW, Schiff MH, Markenson J, Whitmore JB.
    J Rheumatol; 2004 Aug; 31(8):1532-7. PubMed ID: 15290731
    [Abstract] [Full Text] [Related]

  • 12. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis.
    Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE.
    Arthritis Rheum; 2000 Jul; 43(7):1478-87. PubMed ID: 10902749
    [Abstract] [Full Text] [Related]

  • 13. Changes in Health Assessment Questionnaire disability scores over five years in patients with rheumatoid arthritis compared with the general population.
    Sokka T, Kautiainen H, Hannonen P, Pincus T.
    Arthritis Rheum; 2006 Oct; 54(10):3113-8. PubMed ID: 17009231
    [Abstract] [Full Text] [Related]

  • 14. The methotrexate therapeutic response in rheumatoid arthritis.
    Ortendahl M, Holmes T, Schettler JD, Fries JF.
    J Rheumatol; 2002 Oct; 29(10):2084-91. PubMed ID: 12375316
    [Abstract] [Full Text] [Related]

  • 15. Performance of a rheumatoid arthritis records-based index of severity.
    Ting G, Schneeweiss S, Katz JN, Weinblatt ME, Cabral D, Scranton RE, Solomon DH.
    J Rheumatol; 2005 Sep; 32(9):1679-87. PubMed ID: 16142860
    [Abstract] [Full Text] [Related]

  • 16. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
    Kobelt G, Lindgren P, Singh A, Klareskog L.
    Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879
    [Abstract] [Full Text] [Related]

  • 17. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study.
    Gibofsky A, Palmer WR, Goldman JA, Lautzenheiser RL, Markenson JA, Weaver A, Schiff MH, Keystone EC, Paulus HE, Harrison MJ, Whitmore JB, Leff JA.
    Curr Med Res Opin; 2006 Jan; 22(1):169-83. PubMed ID: 16393443
    [Abstract] [Full Text] [Related]

  • 18. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
    Pease C, Pope JE, Truong D, Bombardier C, Widdifield J, Thorne JC, Paul Haraoui B, Psaradellis E, Sampalis J, Bonner A.
    Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
    [Abstract] [Full Text] [Related]

  • 19. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
    Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, Kalsi J, Eames J, Leirisalo-Repo M.
    J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385
    [Abstract] [Full Text] [Related]

  • 20. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis.
    Welsing PM, Fransen J, van Riel PL.
    Arthritis Rheum; 2005 Sep; 52(9):2616-24. PubMed ID: 16142762
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.